Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
IGF-1 LR3 vs Tesamorelin
An educational, source-based comparison of IGF-1 LR3 and Tesamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
- Visceral adipose tissue reduction (approved)
- Cognitive function in older adults (research)
- NAFLD / hepatic fat (research)
- • FDA-approved only for HIV-associated lipodystrophy.
- • May affect glucose tolerance; monitor in at-risk patients.
- • Requires physician oversight.
IGF-1 LR3 vs Tesamorelin — Key differences
- Class: IGF-1 LR3 is classified as Growth Factor, while Tesamorelin is Growth Hormone Axis.
- Primary research focus: IGF-1 LR3 — muscle protein synthesis (preclinical); Tesamorelin — visceral adipose tissue reduction (approved).
- Tag: Growth · Recovery vs Body composition.